A natural weight loss peptide called BRP — discovered by Stanford researchers and published in Nature in April 2026 — reduced appetite by 50% in animal studies without the nausea, constipation, or muscle loss that plague current GLP-1 drugs like Ozempic and Wegovy. The peptide is naturally occurring in the human body, acts directly on the brain's appetite-control centre through a different pathway than semaglutide, and produced fat-specific weight loss in obese mice over 14 days.
This is genuine science — a peer-reviewed Nature publication from a Stanford Medicine lab, not a supplement industry press release. But it's also pre-clinical. BRP has been tested in mice and minipigs, not humans. Clinical trials are planned but haven't started. Anyone selling you "BRP" or a "natural Ozempic alternative" based on this research is ahead of the evidence.
What you can do right now: understand the science, know what lifestyle factors influence the same appetite-regulating systems BRP targets, and separate the legitimate research from the inevitable marketing.
What is the natural weight loss peptide BRP? BRP (BRINP2-related peptide) is a naturally occurring 12-amino-acid peptide identified by Stanford researchers using AI analysis of 2,600+ previously uncharacterised human peptide fragments. Published in Nature (2026), BRP activates POMC neurons in the hypothalamus through the cAMP-PKA-CREB-FOS pathway — different from GLP-1 drugs. In animal studies, a single injection reduced food intake by 50% within one hour. In obese mice, 14 days of daily injections produced fat-specific weight loss with improved glucose and insulin tolerance, without nausea or muscle loss (Coassolo & Svensson, Nature, 2026).
BRP Peptide: What the Study Found
The Stanford team, led by Katrin Svensson and Laetitia Coassolo, used artificial intelligence to screen prohormone fragments — inactive molecules that can be cut into smaller peptides by specific enzymes. They focused on prohormone convertase 1/3, an enzyme linked to obesity when mutated, and identified BRP as a fragment with appetite-suppressing activity.
The key findings
Appetite reduction. A single BRP injection in lean mice and minipigs reduced food consumption by up to 50% within one hour. Minipigs are significant because their metabolic systems more closely mirror human eating patterns than mice.
Fat-specific weight loss. In obese mice, daily injections over 14 days produced an average weight loss of 3 grams — primarily from fat. Control mice gained approximately 3 grams over the same period. The treated animals showed no loss of lean mass.
Metabolic improvements. BRP-treated animals showed improved glucose tolerance and insulin sensitivity — effects that mirror GLP-1 drugs but through a different mechanism.
No GLP-1 side effects. The treated animals showed no changes in movement, water intake, anxiety-like behaviour, or digestion. The nausea and gastrointestinal disruption that affect 30–50% of GLP-1 drug users were absent — because BRP works through a different brain pathway entirely.
The mechanism
BRP activates pro-opiomelanocortin (POMC) neurons in the hypothalamus — the brain's primary appetite-control centre — through the cAMP-PKA-CREB-FOS signalling pathway. This is mechanistically distinct from GLP-1 receptor agonism, which means BRP could potentially be combined with existing GLP-1 drugs for enhanced effect, or used as an alternative for people who can't tolerate GLP-1 side effects.
Natural Appetite Suppressant: What This Means for You Now
What you cannot do
Buy BRP. It's not available commercially. Anyone selling it is selling something else labelled as BRP. Clinical trials haven't begun. The Stanford researchers have co-founded Merrifield Therapeutics to develop BRP, but human trials are likely 2–3 years away from producing results.
Assume it works in humans. Pre-clinical animal data is promising but not proof of human efficacy. Many compounds that work in mice fail in human trials. The Nature publication is a strong starting signal, not a finished product.
What you can do
The appetite-regulating systems that BRP targets — POMC neurons, hypothalamic satiety signalling — are influenced by several lifestyle factors that are within your control right now.
Protein intake. Protein is the most satiating macronutrient. A meta-analysis found that higher protein diets (25–30% of calories) significantly reduce appetite and total caloric intake compared to lower protein diets. The mechanism involves peptide YY and GLP-1 release from the gut — the same appetite-signalling pathways that pharmaceutical interventions target. See our protein guide for the evidence on optimal intake.
Sleep. Sleep deprivation disrupts leptin and ghrelin — the hormones governing hunger and satiety. A single night of poor sleep increases ghrelin (hunger hormone) and decreases leptin (satiety hormone), increasing appetite by approximately 300–400 calories the following day. Your sleep protocol is an appetite regulation protocol.
Resistance training. Resistance training preserves lean mass during weight loss — the variable most strongly associated with long-term weight maintenance. BRP's fat-specific weight loss effect (preserving lean mass while reducing fat) is exactly what resistance training achieves through different mechanisms.
Cortisol management. Chronic cortisol elevation increases appetite for calorie-dense foods via neuropeptide Y upregulation and drives visceral fat storage. Managing cortisol addresses the upstream hormonal environment that influences appetite — the same hypothalamic systems BRP targets.
Start Optimising Everything
Get the free Starter Protocol — one document covering all four pillars: body, mind, wealth, and time. Read it in ten minutes. Act on it today.
Get the Starter Protocol → Free. No spam. Join men who operate on evidence, not opinion.
Peptides for Weight Loss: The Current Landscape
BRP enters a rapidly evolving field. Here's where the major peptide-based weight loss interventions stand as of April 2026.
Approved and available
Semaglutide (Wegovy/Ozempic). GLP-1 receptor agonist. ~15% average body weight loss over 68 weeks. Available as weekly injection and (since January 2026) oral tablet. Most widely prescribed. Side effects: nausea (30–50%), constipation, potential muscle loss.
Tirzepatide (Mounjaro/Zepbound). Dual GLP-1/GIP agonist. ~20% average body weight loss over 72 weeks. Superior to semaglutide in head-to-head trials. Similar GI side effects.
Orforglipron (Foundayo). First small-molecule GLP-1 pill, approved April 2026. Once-daily, no food restrictions. ~15% weight loss. Lower cost than injectable peptides.
In clinical development
Retatrutide. Triple agonist (GLP-1/GIP/glucagon). ~24% weight loss in Phase 2. The most potent weight loss compound in clinical development. Phase 3 expected 2026.
BRP. The Stanford natural peptide. Pre-clinical only. Different mechanism (POMC activation, not GLP-1). Human trials planned but not yet started.
What BRP adds to the picture
The significance of BRP isn't that it's necessarily better than existing drugs — that's unknown until human trials. The significance is threefold:
Different mechanism. It works through POMC neurons, not GLP-1 receptors. This means it could potentially be combined with GLP-1 drugs or used for people who don't respond to or can't tolerate GLP-1 therapy.
Natural occurrence. BRP is endogenous — it already exists in the human body. This raises the question of whether lifestyle factors can upregulate its natural production, though this hasn't been studied yet.
No muscle loss. In animal studies, BRP produced fat-specific weight loss. Current GLP-1 drugs cause 20–40% of total weight loss to come from lean mass. If this preserving effect translates to humans, it would be a significant clinical advantage.
Natural Ozempic Alternative: What Actually Works Now
Until BRP reaches human trials, the evidence-based "natural" approach to the same goal — appetite regulation and fat-specific weight loss — involves stacking the lifestyle factors that influence the same biological systems:
1. High protein diet (1.6–2.2g/kg/day). Protein triggers natural GLP-1 and PYY release from the gut. Each high-protein meal activates satiety signalling through the same pathways that pharmaceutical GLP-1 drugs target — just at a lower magnitude.
2. Resistance training 3–4×/week. Preserves lean mass during caloric deficit. This is the lifestyle equivalent of BRP's fat-specific weight loss effect.
3. Sleep 7–9 hours. Normalises leptin and ghrelin. Protects the hypothalamic appetite regulation that both BRP and GLP-1 drugs target.
4. Moderate caloric deficit (10–20%). Aggressive deficits elevate cortisol, increase appetite, and promote muscle loss — the opposite of what BRP achieves. Moderate deficits produce slower but more sustainable and body-composition-favourable results.
5. Creatine 3–5g daily. Supports training performance during caloric deficit and preserves lean mass.
None of these produce 15–20% body weight loss in 68 weeks. Pharmaceutical peptides are dramatically more powerful for absolute weight loss. But the lifestyle stack produces the same directional effects — appetite regulation, lean mass preservation, metabolic improvement — without side effects, without cost, and without dependency on continued drug administration.
Frequently Asked Questions
What is the natural weight loss peptide discovered by Stanford?
BRP (BRINP2-related peptide) is a naturally occurring 12-amino-acid peptide identified using AI and published in Nature (April 2026). It reduced appetite by 50% in animal studies by activating POMC neurons in the hypothalamus — a different pathway than GLP-1 drugs. In obese mice, daily injections produced fat-specific weight loss without nausea, muscle loss, or digestive side effects. Human clinical trials are planned but haven't started.
Can I buy BRP peptide?
No. BRP is not commercially available. It's a pre-clinical research compound that hasn't been tested in humans. Anyone marketing "BRP" or a "natural Ozempic alternative" based on this research is misrepresenting the science. The Stanford researchers have founded a company (Merrifield Therapeutics) to develop BRP, but human trials are likely 2–3 years from producing results.
Is there a natural alternative to Ozempic?
No single natural compound matches GLP-1 drug efficacy for weight loss. However, high protein intake (triggering natural GLP-1 release), quality sleep (normalising hunger hormones), resistance training (preserving lean mass), and stress management (reducing cortisol-driven appetite) collectively influence the same appetite-regulatory pathways. These produce slower but sustainable results without side effects or dependency.
How does BRP differ from semaglutide?
BRP activates POMC neurons through the cAMP-PKA-CREB-FOS pathway. Semaglutide activates GLP-1 receptors. Different mechanisms mean different side effect profiles — BRP showed no nausea or GI disruption in animals. They could potentially be combined. BRP also preserved lean mass (fat-specific weight loss), while GLP-1 drugs cause 20–40% of weight loss from muscle. BRP is pre-clinical; semaglutide is approved and widely available.
What lifestyle factors influence appetite-regulating peptides?
Protein intake triggers natural GLP-1 and PYY release from the gut. Sleep normalises leptin and ghrelin balance. Exercise improves insulin sensitivity and hypothalamic function. Chronic stress (cortisol) upregulates appetite-stimulating neuropeptides. These lifestyle factors influence the same hypothalamic systems that BRP and GLP-1 drugs target — just at lower magnitudes.
Key Takeaways
- BRP is a genuine scientific discovery — published in Nature by Stanford Medicine, not a supplement marketing claim
- It's pre-clinical — tested in mice and minipigs, not humans. Human trials haven't started
- Different mechanism from GLP-1 drugs — POMC activation, no nausea, fat-specific weight loss in animals
- You cannot buy it yet — and shouldn't trust anyone claiming to sell it
- The lifestyle factors that influence the same appetite pathways — protein, sleep, resistance training, cortisol management — are available now and produce directionally similar effects
References
-
Coassolo L, Svensson K, et al. Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide. Nature. 2025;641(8061):192. DOI: 10.1038/s41586-025-08683-y
-
Stanford Medicine press release. Stanford scientists discover "natural Ozempic" without side effects. ScienceDaily. April 12, 2026.
-
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
-
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
-
Leidy HJ, et al. The role of protein in weight loss and maintenance. American Journal of Clinical Nutrition. 2015.
-
Spiegel K, et al. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels and increased hunger and appetite. Annals of Internal Medicine. 2004.
This is educational content, not medical advice. BRP is a pre-clinical research compound not approved for human use. Consult your doctor before making changes to your health, fitness, or nutrition regimen.